

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number
WO 03/103638 A1

(51) International Patent Classification⁷: A61K 9/28

(21) International Application Number: PCT/US03/17705

(22) International Filing Date: 5 June 2003 (05.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
10/164,744 7 June 2002 (07.06.2002) US
10/431,271 7 May 2003 (07.05.2003) US

(71) Applicant (for all designated States except US): GENEVA PHARMACEUTICALS, INC. [US/US]; 2655 West Midway Boulevard, Broomfield, CO 80038 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): PATEL, Mahendra, R. [US/US]; 18 Timothy Lane, East Brunswick, NJ 08816 (US). MATHARU, Amol, Singh [IN/US]; 68 Encampment Drive, Bedminster, NJ 07921 (US). WU, Chuanbin [CN/US]; 53 Lindsay Court, Franklin Park, NJ 08823 (US). PATEL, Ashish, Anilbhai [IN/US]; 20 New Road, Apt. 6A, Kendall Park, NJ 08824 (US).

(74) Agent: MAJKA, Joseph; Novartis, Corporate Intellectual Property, One Health Plaza, Bldg. 430/2, East Hanover, NJ 07936 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING BENZIMIDAZOLE COMPOUNDS

(57) Abstract: An oral pharmaceutical composition in a solid dosage form comprising: a) a single core comprising a proton pump inhibitor and a lubricant, wherein said single core has an exterior surface; b) an enteric compression coating comprising a polymer and a lubricant, wherein said enteric compression coating is on the exterior surface of said single core, without a separating layer between said single core and said enteric compression coating; and c) optionally, a polymer overcoating on said enteric compression coating.

WO 03/103638 A1

**STABILIZED PHARMACEUTICAL COMPOSITIONS CONTAINING BENZIMIDAZOLE
COMPOUNDS**

Field of the Invention

The present invention relates to new, stabilized compositions containing proton-pump inhibitors (PPI) from the benzimidazole class of compounds.

Background of the Invention

Certain benzimidazoles are anti-ulcerous compounds known for decreasing gastric acid secretion. However, these compounds, also known as PPI, are susceptible to degradation/transformation in acidic reacting and neutral media. The degradation is catalyzed by acidic reacting compounds and the PPIs are usually stabilized in mixtures with alkaline reacting compounds. In respect to the stability properties of the benzimidazole compounds mentioned above, it is obvious that those in an oral solid dosage form must be protected from contact with the acidic reacting gastric juice and the active substance must be transferred in intact form to that part of the gastrointestinal tract where pH is less acidic, neutral or alkaline and where rapid absorption of the pharmaceutically active substance, i.e., the benzimidazole derivative, can occur.

U.S. Patent No. 4,853,230 has shown that a pharmaceutical dosage form of these benzimidazole derivatives can be protected from contact with acidic gastric juice by an enteric coating layer. Such preparations contain an alkaline core material comprising the active substance, a separating layer and an enteric coating layer. Ordinary enteric coating layers, however, comprise compounds which contain acidic groups. If covered with such an enteric coating layer, the acid labile substance may rapidly decompose by direct or indirect contact with the acidic groups resulting in discoloration of the content and loss in content of the active compound with the passage of time. The discoloration can be avoided by applying some type of separating layer between the core material comprising the susceptible these benzimidazole derivatives and the enteric coating layer.

U.S. Patent Nos. 4,628,098; 4,853,230; 4,026,560; 5,689,333; 5,045,321; 5,093,132; 5,433,959; and 6,013,281 teach various stabilizing agents for these benzimidazole derivatives in the core tablets. These references also show that such compounds are stable

in the presence of basic inorganic salts of magnesium, calcium, potassium and sodium. The stability is further consolidated by separating the acidic components of the enteric coat by an intermediate coating, where the core material are pellets.

U.S. Patent No. 6,013,281 also discloses that a separating layer is formed *in situ* by direct application of an acidic enteric material on to the alkaline core containing the PPI.

Tabata et al., "Stabilization of New Antiulcer Drug (lansoprazole) in the Solid Dosage Forms", Drug. Dev. Ind. Pharm., Vol. 18, pp. 1437-1447 (1992) showed that the rate of degradation of lansoprazole, a representative of the benzimidazole series, was reduced to negligible in pH higher than 7.

WO 98/00115 teaches the use of aqueous application of partially neutralized enteric polymer applied directly onto the reactive core. Similar application was disclosed in U.S. Patent No. 5,225,202.

The need to use a separating layer requires the application of two separate functional coating operations which increases the length of the manufacturing process and the cost of the product. It would desirable to provide an alternative oral dosage composition containing a PPI, that does not rely upon the use of an intermediate or separating layer to stabilize the PPI contained therein.

Summary of the Invention

Applicants have developed an oral pharmaceutical composition in the form of a tablet that avoids the need to use a separating layer to separate the tablet core containing the PPI from the enteric coating layer in a tablet dosage form.

Thus, in one embodiment, the present invention is directed toward an oral pharmaceutical composition in a solid dosage form comprising:

- a) a single core comprising a proton pump inhibitor and a lubricant, wherein said single core has an exterior surface;
- b) an enteric compression coating comprising a polymer and a lubricant, wherein said enteric compression coating is on the exterior surface of said single core, without a separating layer between said single core and said enteric compression coating; and
- c) optionally, a polymer overcoating on said enteric compression coating.

In another embodiment, the present invention is directed towards an oral pharmaceutical composition in a solid dosage form comprising:

- a) a single core comprising a proton pump inhibitor, a disintegrant, a filler and a lubricant, wherein said single core has an exterior surface;
- b) an enteric compression coating comprising a polymer and a lubricant, wherein said enteric compression coating is on the exterior surface of said single core, without a separating layer between said single core and said enteric compression coating; and
- c) optionally, a polymer overcoating on said enteric compression coating

In another embodiment the present invention is directed toward an oral pharmaceutical composition in a solid dosage form comprising:

- a) a single core comprising a proton pump inhibitor and a lubricant, said single core being essentially free of an alkaline reacting agent, wherein said single core has an exterior surface;
- b) an enteric compression coating comprising a polymer and a lubricant, wherein said enteric compression coating is on the exterior surface of said single core, without a separating layer between said single core and said enteric compression coating; and
- c) optionally, a polymer overcoating on said enteric compression coating.

In another embodiment, the present invention is directed towards a process for preparing an oral pharmaceutical composition in a solid dosage form comprising:

- a) forming a single core comprising a proton pump inhibitor and a lubricant, wherein said single core has an exterior surface;
- b) compression coating an enteric polymer comprising a proton pump inhibitor and a lubricant onto the exterior surface of said single core, in the absence of water and organic solvents, and without forming a separating layer between said single tablet core and said enteric coating; and
- c) optionally, applying a polymer overcoating on said enteric compression coating.

The single tablet core may contain a PPI selected from the group consisting of rabeprazole, omeprazole, esomeprazole, lansoprazole, leminoprazole, pantoprazole or mixtures thereof.

The enteric coating may contain a polymer selected from cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate (HPMCAS), hydroxypropylmethylcellulose phthalate (HPMCP), polyvinylacetate phthalate, carboxymethylethylcellulose, acrylic acid polymers and co-polymers and methacrylic acid polymers and co-polymers or combinations thereof.

The present invention has the advantage of providing an oral pharmaceutical composition containing a labile PPI in the form of a tablet that can provide improved stability of the PPI contained therein against degradation and/or discoloration by moisture and/or heating.

Another advantage of the present invention is that it provides an oral pharmaceutical composition containing a labile PPI in the form of a tablet whose design and/ or construction is greatly simplified over other known tableted compositions.

Another advantage of the present invention is that it provides an oral pharmaceutical composition containing a labile PPI that allows control of the release rate of said labile PPI within wide margins.

Another advantage of the present invention is that it provides a process for preparing an oral pharmaceutical composition containing a labile PPI, that can eliminate the use of water or organic solvents during coating of the tablet core, i.e., can be solvent-free.

Another advantage of the present invention is that it provides a process for preparing an oral pharmaceutical composition containing a labile PPI that can eliminate the need for heating during process, i.e., can be processed at ambient temperatures.

Another advantage of the present invention is that it provides an oral pharmaceutical composition and a process for preparation thereof, containing a labile PPI in the form of a tablet that does not require a separating layer to separate the core unit containing the acid-labile PPI from the enteric coating.

Another advantage of the present invention is that it provides a process for preparing an oral pharmaceutical composition, containing a labile PPI in the form of a tablet that can prevent the *in situ* formation of a separating layer between the core unit containing the acid-labile PPI from the enteric coating.

Another advantage of the present invention is that it provides a process for preparing an oral pharmaceutical composition containing a labile PPI in the form of a tablet, that can be carried out or produced using conventional pharmaceutical equipment.

Detailed Description of the Invention


Utilization of an enteric material as a non-interactive dry application of an otherwise highly interactive material has not been discussed in the prior art, and has not been disclosed in any of the previous patents.

The PPI in an oral solid dosage form should be protected from contact with the acid reacting gastric juice and the active substance should be transferred in intact form to that part of the gastrointestinal tract where the pH is less acidic, neutral or alkaline and where rapid absorption of the pharmaceutically active substance can occur.

A) Core

The terms "tablet core", "core", "single core", "core tablet", "single tablet core" or "single tablet core unit" have the same meaning and can be used interchangeably. Also, the terms "benzimidazole", "benzimidazole compound", "proton pump inhibitor" and "PPI" have the same meaning and can be used interchangeably.

Suitable benzimidazole compounds that can be employed as an active ingredient in the composition of the present invention include those of formula (I)



wherein

R^1 is hydrogen, alkyl, halogen, cyano, carboxy, carboalkoxy, carboalkoxyalkyl, carbamoyl, carbamoylalkyl, hydroxy, alkoxy, hydroxyalkyl, trifluoromethyl, acyl, carbamoyloxy, nitro, acyloxy, aryl, aryloxy, alkylthio or alkylsulfinyl;

R^2 is hydrogen, alkyl, acyl, carboalkoxy, carbamoyl, alkylcarbamoyl, dialkylcarbamoyl, alkylcarbonylmethyl, alkoxycarbonylmethyl or alkylsulfonyl;

R^3 and R^5 are the same or different and each can be hydrogen, alkyl, alkoxy or alkoxyalkoxy;

R^4 is hydrogen, alkyl, alkoxy which may optionally be fluorinated, or alkoxyalkoxy; and

m is an integer of 0 through 4.

Representative examples of such PPIs include rabeprazole, omeprazole, esomeprazole, pariprazole, lansoprazole, leminoprazole, pariprazole, pantoprazole or mixtures thereof.

The PPIs employed in the present invention may be used in neutral form or in the form of an alkaline metal salt, such as for instance, the salt of potassium, sodium, lithium, magnesium and/or calcium. Also, the benzimidazole compounds cited above may be used in a neutral form, in a racemic mixture, in the form of a substantially pure enantiomer thereof, as an alkaline salt of the racemic mixture or a single enantiomer, or combinations thereof. The amount of PPI can range from about 5% to about 75% by weight, from about 10% to about 70% by weight or from about 15% to about 60% by weight of the oral pharmaceutical composition. Alternatively, the oral pharmaceutical composition or tablet can contain a known mass of the PPI, such as 10, 15, 20, 30 or 40 mg.

The term "labile" refers to the property that the PPI are susceptible to degradation in the presence of acid and neutral media, humidity and/or elevated temperatures. For example, degradation of PPI can be catalyzed by acids or acid containing compounds. The PPI may also be unstable in the presence of water or high humidity.

Suitable inert fillers that can be used in the core include lactose, mannitol, starch, sucrose, glucose, hydroxypropyl cellulose, low-substituted hydroxypropyl cellulose, ethylcellulose, hydroxypropyl methylcellulose phthalate, diacetylated monoglycerides, talc, titanium dioxide and other excipients. The amount of filler can range from about 10% to about 90% by weight of the tablet.

Suitable disintegrants that can be used in the core can include sodium starch glycolate or sodium crosscarmellose. The amount of disintegrant can range from about 0.5% to about 30% by weight of the tablet.

Suitable lubricants that can be used in the core can include dry or solid lubricants, such as magnesium stearate, calcium stearate, sodium stearate, sodium stearyl fumarate and waxes, such as polyethylene glycol (solid form) and carnauba wax. The lubricant can be employed in both the enteric compression coating and in the core. The amount of lubricant can range from about 0.5 to about 30% by weight of each tablet or solid dosage form component, also from about 5 to about 25 percent by weight, also from about 10 to about 15 percent by weight. Alternatively, the amount of lubricant in the pharmaceutical composition can range from about 0.1% to about 10 - 20%, also about 0.2% to about 6% by weight. Alternatively, the amount of lubricant in the tablet can range from about 0.01 parts to about

1.5 parts by weight of the lubricant per one part PPI (about 0.01-1.5 parts lubricant:one part PPI).

The PPI is mixed with suitable pharmaceutical constituents, such as those described above for the fillers, disintegrants and lubricants and the resulting mixture is compressed into the core or tablet core unit. Moreover, the core tablet core of the present invention should be essentially free of alkaline reacting agents or compounds, such as those cited in U.S. Patent No. 6,013,281. The PPI should not be seeded or layered prior to being compressed into the core unit. The size of the formulated core material is approximately between about one and about 20 mm and preferably between about 3 mm and about 15 mm. The manufactured core tablet containing the PPI can be covered with an enteric outer coating or layer. After preparation, the single core tablet has an exterior surface where the enteric outer coating is applied or coated.

B) Enteric Compression Coating or Layer

The terms "enteric coating", "enteric compression coating", "enteric compression layer", "enteric outer coating", "enteric layer" or "enteric outer layer" have the same meaning and can be used interchangeably. The enteric coating should be inert or substantially non-interacting with the single, tablet core containing the PPI. The enteric coating may contain ingredients, such as one or more polymers, release rate agents, lubricants, anti-tacking agents, colorants, pigments or other-additives to obtain a tablet of good appearance. The amount of enteric coating in the tablet can range from about 0.1 - 0.4 parts to about 3 parts by weight of enteric coating per one part by weight tablet core (about 0.1 - 0.4 to 3 parts by weight enteric coating:one part tablet core). However, the enteric outer coating does not contain any PPI or other active drug ingredient.

Suitable polymers that can be used in the enteric coating can include anionic co-polymers based on methacrylic acid esters, commercially available as Eudragit L 100 and Eudragit S 100, trademarks of Rohm, GmbH & Co., KG, Darmstadt, Germany. This enteric coating is insoluble below pH 5 and is thus resistant to gastric fluid. By salt formation in the neutral or weakly alkaline medium of the intestinal fluid, the enteric coating dissolves stepwise at pH values greater than 5.5-7.5. Another suitable polymer that can be used includes HPMCP or HPMCAS, commercially available from the Shin-Etsu Chemical Co. Ltd. A sole polymer can be employed such as HPMCAS or a mixture of polymers can be used, such as Eudragit and HPMCP. Thus, polymers can be cellulose acetate phthalate, HPMCAS, HPMCP, polyvinylacetate phthalate, carboxymethylethylcellulose, acrylic acid polymers and co-

polymers and methacrylic acid polymers and co-polymers. The non-interacting property of such enteric coatings can be obtained or enhanced by neutralizing free acids in the enteric polymer with an inorganic or organic alkaline material, such as sodium hydroxide, magnesium hydroxide, meglumine and the like. The neutralized polymer results in enhanced stabilization of the tablet core. The amount of each polymer employed in the enteric coating can range from about 5% to about 99% by weight of the composition.

Suitable release rate agents that can be used in the enteric coating can include lactose, mannitol, starch, sucrose, glucose, hydroxypropylcellulose, low-substituted hydroxypropylcellulose, ethylcellulose, HPMCP, diacetylated monoglycerides, talc or titanium dioxide. The amounts of release agent employed in the enteric coating can range from about 0.5% to about 95% by weight of the composition.

Suitable lubricants that can be used in the core can include dry or solid lubricants, such as magnesium stearate, calcium stearate, silicon dioxide, or sodium stearate and waxes, such as carnauba wax. The lubricant can be employed in both the enteric compression coating and in the core or tablet core. The amount of lubricant in either the enteric coating layer or in the core can range from about 0.5 to about 30% by weight of each tablet or solid dosage form component, also from about 5 to about 25 percent by weight, also from about 10 to about 15 percent by weight. Alternatively, the amount of lubricant in the pharmaceutical composition can range from about 0.1% to about 10 - 20%, also about 0.2% to about 6% by weight. Alternatively, the amount of lubricant in the tablet can range from about 0.01 parts to about 1.5 parts by weight of the lubricant per one part PPI (about 0.01-1.5 parts lubricant:one part PPI).

The ingredients used in the enteric coating are dry or solid (with the exception of the optional polymer over-coating, discussed below) and can be blended or mixed together in the absence of water or organic solvents. The dry blend or mixture can be compressed (i.e., compression-coated) directly onto the exterior surface of the core or tablet core, using conventional procedures. One skilled in the art can utilize a range of compression forces or tablet hardnesses which provide the desired attributes for the enteric compression coating, such as acid protection or release in the post-stomach region. For example, one can prepare a series of tablet samples at different compression forces or tablet hardnesses and select a range which meets desired physical and performance attributes, such as tablet friability and dissolution profiles. These attributes are also described in the United States Pharmacopeia (USP) 26, United States Pharmacopeial Convention Inc., (2003) and Chapter 724 (drug release) – Delayed –Release (enteric-coated) articles – general drug release

standards. For example, the range of hardnesses for a tablet with the enteric compression coating can range from about 4 SCU to about 30 SCU, also from about 7 to about 15 SCU. The compressive forces can range from about 0.1 ton to about 3 tons, also from about 0.3 to about 2 tons, also from about 0.5 ton to about 1.5 tons. Alternatively, the dry mixture can be sprayed or dispersed directly onto the core or tablet core and then compressed as described above. The dry blend or mixture that is compressed onto the exterior surface of the core or tablet core forms the enteric compression coating for the pharmaceutical composition. After the enteric compression coating is applied to the core or tablet core, there is no separating layer between the core and the enteric compression coating.

C. Optional Polymer Over-Coating

Tablets with the enteric coating are then covered with optionally one or more finishing polymer over-coating or tablet film coat(s) or layer(s) to obtain tablets of good appearance, smoothness, color or functionality, such as modified release. The maximum thickness of the applied over-coating layer(s) is normally limited by processing conditions and the desired dissolution or release profile. For example, the tablet film(s) can be a thin coat as compared to the enteric coating. The polymer over-coating can be water soluble or water soluble/swellable in water or have a solubility that is pH dependent. Further, the over-coating can be rapidly disintegrating or even insoluble in water. The materials for the over-coating layer can be pharmaceutically acceptable excipients, such as the same polymers used in the enteric coating layer, sugar, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, polyvinyl acetate, hydroxypropylcellulose, methylcellulose, ethylcellulose, hydroxypropylmethylcellulose, acrylic acid co-polymers, carboxymethylcellulose sodium, phthalate, HPMCAS, Eudragit (Rohm Pharma Co., West Germany, acrylate co-polymer, amionic in character), polyvinylacetaldiethylaminoacetate, water soluble salts of enteric coating polymers, and waxes, used alone or in mixtures. Additives, such as plasticizers, colorants, pigments, fillers, anti-tacking and anti-static agents, such as for instance magnesium stearate, titanium dioxide, talc and other additives may also be included into the over-coating layer(s). However, the polymer over-coating does not contain any PPI or other active drug ingredient. The amount of polymer coating in the tablet can range from about 0.01 parts to about 1 part by weight of polymer coating per one part by weight tablet core (about 0.4-3 parts by weight enteric coating:one part tablet core).

The polymer over-coating or tablet film coat can be applied to the enteric coating layered tablet by spraying, coating or layering procedures in suitable equipment, such as coating pan, coating granulator or in a fluidized bed apparatus. In such procedures, water or other

solvents may be used to solubilize the materials used for the polymer over-coating or tablet film coat.

The invention can be illustrated by the following examples, which are non-limiting as to the scope of the claimed invention.

Example 1. Tablet for Delayed Sustained Release

Tablet core	% w/w
Rabeprazole sodium	10
Lactose F.F.	76
Sodium starch glycolate	9
Magnesium stearate	5

The tablet core is prepared by dry mixing rabeprazole sodium with lactose F.F., sodium starch glycolate and magnesium stearate. The dry mixture is compressed with a suitable tablet press into 200 mg core tablets containing 20 mg of rabeprazole sodium which are 0.31" (7.9 mm) in diameter and 0.16" (4.1 mm) in thickness.

Tablet core	% w/w
Eudragit L100-55	49.0
HPMCP HP-55	24.5
Lactose F.F.	24.5
Magnesium stearate	2.0

The enteric coating is prepared by dry blending or mixing Eudragit L100-55, HPMCP HP-55, Lactose F.F. and magnesium stearate. The core tablet is compression-coated using the resulting dry blend to produce 600 mg tablets, 0.40" (10.2 mm) in diameter and 0.25" (6.35 mm) in thickness.

The compression-coated tablets are over-coated with 5% hydroxypropylmethylcellulose based on the total tablet weight.

The release of the drug from the tablets is monitored using a dissolution tester, in which 900 mL of simulated gastric fluid (SGF), without enzyme is maintained at 37°C and used as the dissolution medium for the first 2 hours. The USP 2 dissolution method is used at a rotation speed of 50 rpm. For the next hour, phosphate buffer is used as a media.

Delayed release of rabeprazole sodium is obtained after a period of about 2 hours in SGF dissolution media. The dissolution in phosphate buffer (average, n=6) is as follows:

Time	% dissolved
<i>Media: SGF</i>	
1 hour	0
2 hours	0
<i>Media: phosphate buffer</i>	
5 minutes	0.9
10 minutes	2.0
15 minutes	3.5
30 minutes	38.7
45 minutes	89.4
60 minutes	107.5

In the following Examples 2-5, the dimensions of the tablet cores and polymer coat are the same as those in Example 1.

Example 2. Tablet for Delayed Sustained Release

Tablet core	% w/w
Rabeprazole sodium	10.0
Lactose F.F.	76.0
Sodium starch glycolate	9.0
Magnesium stearate	5.0

Enteric outer-coating	% w/w
Eudragit L100-55	42.5
HPMCP HP-55	31.0
Lactose F.F.	24.5
Magnesium stearate	2.0

Delayed-release tablets are prepared and tested as for Example 1.

Delayed release of the active ingredient is obtained after a period of about 2 hours in SGF and about 1 hour in phosphate buffer solution.

Example 3. Tablet for Delayed Sustained Release

Tablet core	% w/w
Rabeprazole sodium	10.00
Lactose F.F.	76.00
Sodium starch glycolate	9.00
Magnesium stearate	5.00

Enteric outer layer	% w/w
Eudragit L100-55	36.75
HPMCP HP-55	36.75
Lactose F.F.	24.50
Magnesium stearate	2.00

Delayed-release tablets are prepared and tested as for Example 1, except that the compression-coated tablets are over-coated with 3% Eudragit polymer based on the total tablet weight.

The release of the drug from the tablets is monitored using a dissolution, in which 900 mL of SGF, without enzyme, is maintained at 37°C and used as the dissolution medium for the first 2 hours. The USP 2 dissolution method is used at a rotation speed of 50 rpm. For the next hour, phosphate buffer is used as a media.

Delayed release of rabeprazole sodium is obtained after a period of about 2 hours in SGF dissolution media. The dissolution in phosphate buffer (average, n=6) is as follows:

Time	% dissolved
<i>Media: SGF</i>	
2 hours	0.8
<i>Media: phosphate buffer</i>	
5 minutes	1.3
10 minutes	3.6
15 minutes	11.4
30 minutes	49.3
45 minutes	77.8
60 minutes	100.9

Example 4. Tablet for Delayed Sustained Release

Tablet core	% w/w
Rabeprazole sodium	10
Lactose F.F.	69
Sodium starch glycolate	20
Magnesium stearate	1

The tablet core is prepared by dry mixing rabeprazole sodium with lactose F.F., sodium starch glycolate and magnesium stearate. The dry mixture is compressed with a suitable tablet press into 200 mg core tablets containing 20 mg of rabeprazole sodium which are 0.31" (7.9 mm) in diameter and 0.16" (4.1 mm) in thickness.

Enteric outer layer	% w/w
Eudragit L100-55	49.0
HPMCP HP-55	24.5
Lactose F.F.	24.5
Magnesium stearate	2.0

The enteric outer layer is prepared by dry blending or mixing the above excipients and compression-coating the core tablet with the resulting blend to produce 600 mg tablets, 0.40" (10.2 mm) in diameter and 0.25" (6.35 mm) in thickness.

The compression-coated tablets are over-coated with 5% hydroxypropylmethylcellulose based on the total tablet weight.

The release of the drug from the tablets is monitored using a dissolution, in which 900 mL of SGF, without enzyme is maintained at 37°C and used as the dissolution medium for the first 2 hours. The USP 2 dissolution method is used at a rotation speed of 50 rpm. For the next hour, phosphate buffer is used as a media.

Delayed release of rabeprazole sodium is obtained after a period of about 2 hours in SGF dissolution media. The dissolution in phosphate buffer (average, n=6) is as follows:

Time	% dissolved
<i>Media: SGF</i>	
2 hours	0.6
<i>Media: phosphate buffer</i>	
5 minutes	1.3
10 minutes	1.9
15 minutes	3.3
30 minutes	12.6
45 minutes	29.8
60 minutes	46.7

Example 5. Tablet for Delayed Sustained Release

Tablet core	% w/w
Rabeprazole sodium	10.00
Lactose F.F.	69.00
Sodium starch glycolate	20.00
Magnesium stearate	1.00

Enteric outer layer	% w/w
Eudragit L 100-55	36.75
HPMCP HP-55	36.75
Lactose F.F.	24.50
Magnesium stearate	2.00

Delayed-release tablets are prepared and tested as for Example 1.

Delayed release of the active ingredient is obtained after a period of about 2 hours in SGF and about 1 hour in phosphate buffer solution.

Example 6. Tablet for Delayed Sustained Release

Tablet core	% w/w
lansoprazole sodium	15.0
Lactose F.F.	71.0
Sodium starch glycolate	9.0
Magnesium stearate	5.0

Enteric outer layer	% w/w
Eudragit L100-55	24.5
HPMCP HP-55	49.0
Lactose F.F.	24.5
Magnesium stearate	2.0

Delayed-release tablets are prepared and tested as for Example 1.

Delayed release of the active ingredient is obtained after a period of about 2 hours in SGF and about 1 hour in phosphate buffer solution.

Example 7. Tablet for Delayed Sustained Release

Tablet core	% w/w
Pantoprazole sodium	20.0
Lactose F.F.	66.0
Sodium starch glycolate	9.0
Magnesium stearate	5.0

Enteric outer layer	% w/w
Eudragit L100-55	24.5
HPMCP HP-55	49.0
Lactose F.F.	24.5
Magnesium stearate	2.0

Delayed-release tablets are prepared and tested as for Example 1.

Delayed release of the active ingredient is obtained after a period of about 2 hours in SGF and about 1 hour in phosphate buffer solution.

Example 8. Tablet for Delayed Sustained Release

Tablet core	% w/w
Omeprazole	10.00
Lactose F.F.	69.00
Sodium starch glycolate	20.00
Magnesium stearate	1.00

Enteric outer layer	% w/w
Eudragit L100-55	36.75
HPMCP HP-55	36.75
Lactose F.F.	24.50
Magnesium stearate	2.00

Delayed-release tablets are prepared and tested as for Example 1.

Delayed release of the active ingredient is obtained after a period of about 2 hours in SGF and about 1 hour in phosphate buffer solution.

Example 9. Tablet for Delayed Sustained Release

Tablet core	% w/w
Pariprazole	10.00
Lactose F.F.	69.00
Sodium starch glycolate	20.00
Magnesium stearate	1.00

Enteric outer layer	% w/w
Eudragit L100-55	36.75
HPMCP HP-55	36.75
Lactose F.F.	24.50
Magnesium stearate	2.00

Delayed-release tablets are prepared and tested as for Example 1.

Delayed release of the active ingredient is obtained after a period of about 2 hours in SGF and about 1 hour in phosphate buffer solution.

Example 10. Tablet for Delayed Sustained Release

Tablet core	% w/w
Lemiprazole	10.00
Lactose F.F.	69.00
Sodium starch glycolate	20.00
Magnesium stearate	1.00

Enteric outer layer	% w/w
Eudragit L100-55	36.75
HPMCP HP-55	36.75
Lactose F.F.	24.50
Magnesium stearate	2.00

Delayed-release tablets are prepared and tested as for Example 1.

Delayed release of the active ingredient is obtained after a period of about 2 hours in SGF and about 1 hour in phosphate buffer solution.

Example 11. Tablet for Delayed Sustained Release

Tablet core	% w/w
Esomeprazole	10.00
Lactose F.F.	69.00
Sodium starch glycolate	20.00
Magnesium stearate	1.00

Enteric outer layer	% w/w
Eudragit L100-55	36.75
HPMCP HP-55	36.75
Lactose F.F.	24.50
Magnesium stearate	2.00

Delayed-release tablets are prepared and tested as for Example 1.

Delayed release of the active ingredient is obtained after a period of about 2 hours in SGF and about 1 hour in phosphate buffer solution.

Example 12. Development of Delayed Release Tablets Coated with Enteric Polymers by Using Compression Coating Techniques

Purpose. To investigate compression coating as a technique for delayed drug release using enteric polymers. Enteric coating has been typically achieved by using film coating with pH sensitive polymers.

Methods. Drug-containing tablets were coated with enteric coating polymer by using compression coating technique. Delayed release properties, compressibility, and stability were evaluated by applying different compression coating formulations, coating levels, and enteric coating polymer types. Drug release is monitored in vitro in 0.1 N HCl solution for 2 hours and then in pH 7.4 phosphate buffer medium for another 60 minutes using USP apparatus II. Formulation stability is evaluated by comparing compression coating formulation and aqueous enteric coating formulation and by storing at room temperature and at 40 °C/75% relative humidity conditions for 3 months. Impurity of the drug in the formulations was determined at initial time, one month, two months, and three months of storage time by HPLC method.

Results. Acid protection is achieved and found to be dependent upon enteric coating levels and compression forces. However, drug release rate in the pH 7.4 phosphate buffer medium are also affected with higher enteric coating level and compression force, which could be ascribed to lower permeability of the compression coating layer. Dissolution results for the optimized formulation show adequate enteric protection and resistance to drug release in 0.1 N HCl while greater than 80% drug is released in pH 7.4 phosphate buffer medium in 60 minutes. This is comparable to enteric polymer coated tablets produced by aqueous coating method. Stability data showed that the total impurity of the formulation could be significantly improved as compared to the aqueous film coating formulation for an acid labile drug.

Conclusion. The novel delayed release formulation could be optimized and developed by compression coating with enteric coating polymer formulations. This technique of providing enteric protection is particularly useful where the drug is highly reactive to an aqueous environment during processing.

CLAIMS

1. An oral pharmaceutical composition in a solid dosage form comprising:
 - a) a single core comprising a proton pump inhibitor and a lubricant, wherein said single core has an exterior surface;
 - b) an enteric compression coating comprising a polymer and a lubricant, wherein said enteric compression coating is on the exterior surface of said single core, without a separating layer between said single core and said enteric compression coating; and
 - c) optionally, a polymer overcoating on said enteric compression coating.
2. The oral pharmaceutical composition of claim 1 wherein said single core comprises a proton pump inhibitor selected from the group consisting of rabeprazole, omeprazole, esomeprazole, lansoprazole, leminoprazole, pantoprazole or mixtures thereof.
3. The oral pharmaceutical composition of claim 1 wherein said single core comprises a proton pump inhibitor that is rabeprazole.
4. The oral composition of claim 1 containing the sodium salt of rabeprazole.
5. The oral pharmaceutical composition of claim 1 wherein said enteric compression coating comprises a polymer selected from cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose phthalate, polyvinylacetate phthalate, carboxymethylethylcellulose, acrylic acid polymers and copolymers and methacrylic acid polymers and copolymers or combinations thereof.
6. The oral pharmaceutical composition of claim 1 in the form of a tablet.
7. An oral pharmaceutical composition in a solid dosage form comprising:
 - a) a single core comprising a proton pump inhibitor, a disintegrant, a filler and a lubricant, wherein said single core has an exterior surface;
 - b) an enteric compression coating comprising a polymer and a lubricant, wherein said enteric compression coating is on the exterior surface of said single core, without a

- separating layer between said single core and said enteric compression coating;
and
- c) optionally, a polymer overcoating on said enteric compression coating.
8. The oral pharmaceutical composition of claim 7 wherein said single core comprises a proton pump inhibitor selected from the group consisting of rabeprazole, omeprazole, esomeprazole, lansoprazole, leminoprazole, pantoprazole or mixtures thereof.
9. The oral pharmaceutical composition of claim 7 wherein said single core comprises a proton pump inhibitor that is rabeprazole.
10. The oral composition of claim 7 containing the sodium salt of rabeprazole.
11. The oral pharmaceutical composition of claim 7 wherein said enteric compression coating comprises a polymer selected from cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose phthalate, polyvinylacetate phthalate, carboxymethylethylcellulose, acrylic acid polymers and copolymers and methacrylic acid polymers and copolymers or combinations thereof.
12. The oral pharmaceutical composition of claim 7 in the form of a tablet.
13. An oral pharmaceutical composition in a solid dosage form comprising:
- a) a single core comprising a proton pump inhibitor and a lubricant, said single core being essentially free of an alkaline reacting agent, wherein said single core has an exterior surface;
- b) an enteric compression coating comprising a polymer and a lubricant, wherein said enteric compression coating is on the exterior surface of said single core, without a separating layer between said single core and said enteric compression coating;
and
- c) optionally, a polymer overcoating on said enteric compression coating.
14. The oral pharmaceutical composition of claim 13 wherein said single core comprises a proton pump inhibitor selected from the group consisting of rabeprazole, omeprazole, esomeprazole, lansoprazole, leminoprazole, pantoprazole or mixtures thereof.

15. The oral pharmaceutical composition of claim 13 wherein said single core comprises a proton pump inhibitor that is rabeprazole.
16. The oral composition of claim 13 containing the sodium salt of rabeprazole.
17. The oral pharmaceutical composition of claim 13 wherein said enteric compression coating comprises a polymer selected from cellulose acetate phthalate, hydroxypropylmethylcellulose acetate succinate, hydroxypropylmethylcellulose phthalate, polyvinylacetate phthalate, carboxymethylethylcellulose, acrylic acid polymers and copolymers and methacrylic acid polymers and copolymers or combinations thereof.
18. The oral pharmaceutical composition of claim 13 in the form of a tablet.
19. A process for preparing an oral pharmaceutical composition in a solid dosage form comprising:
- a) forming a single core comprising a proton pump inhibitor and a lubricant, wherein said single core has an exterior surface;
 - b) compression coating an enteric polymer comprising a proton pump inhibitor and a lubricant onto the exterior surface of said single core, in the absence of water and organic solvents, and without forming a separating layer between said single tablet core and said enteric coating; and
 - c) optionally, applying a polymer overcoating on said enteric compression coating.

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 03/17705

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61K9/28

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 00 78284 A (LAHAV RAFFAEL ; AZOULAY VALERIE (IL); DEXCEL LTD (IL)) 28 December 2000 (2000-12-28) page 3, line 26 - page 4, line 14 examples 1,2	1-19
A	US 6 174 548 B1 (KOSITPRAPA UNCHALEE ET AL) 16 January 2001 (2001-01-16) column 1, line 33 - line 55 examples	1-19
A	WO 02 26210 A (PELLONI CHRISTOPHER L ; CULLEN DAN (US); GENEVA PHARMACEUTICALS INC) 4 April 2002 (2002-04-04) page 2, line 5 - line 28 examples	1-19

☐ Further documents are listed in the continuation of box C☒ Patent family members are listed in annex

* Special categories of cited documents:

A document defining the general state of the art which is not considered to be of particular relevance

E earlier document but published on or after the international filing date

L document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

O document referring to an oral disclosure, use, exhibition or other means

P document published prior to the international filing date but later than the priority date claimed

T later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

X document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

Y document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

Z document member of the same patent family

Date of the actual completion of the international search

12 November 2003

Date of mailing of the international search report

27/11/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax. (+31-70) 340-3016

Authorized officer

Rankin, R

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US 03/17705

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1, 7, 13, 19
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 1, 7, 13, 19

Present claims 1, 7, 13, 19 relate to an extremely large number of possible compounds. In fact, the claims contain so many options, variables, possible permutations and provisos that a lack of clarity within the meaning of Article 6 PCT arises to such an extent as to render a meaningful search of the claims impossible. Consequently, the search has been carried out for those parts of the application which do appear to be clear, namely the compounds named in claim 2.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 03/17705

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 0078284	A	28-12-2000	AU 5423200 A	09-01-2001
			CA 2377605 A1	28-12-2000
			EP 1187599 A1	20-03-2002
			WO 0078284 A1	28-12-2000
<hr/>				
US 6174548	B1	16-01-2001	AU 5793799 A	21-03-2000
			CA 2342209 A1	09-03-2000
			EP 1107735 A1	20-06-2001
			JP 2002523443 T	30-07-2002
			WO 0012064 A1	09-03-2000
			US 6602522 B1	05-08-2003
<hr/>				
WO 0226210	A	04-04-2002	AU 9690801 A	08-04-2002
			WO 0226210 A2	04-04-2002
			US 2002064555 A1	30-05-2002
<hr/>				